<DOC>
	<DOCNO>NCT00239252</DOCNO>
	<brief_summary>Efficacy safety compare interferon alfacon-1 alone concomitant dose interferon alfacon-1 ribavirin hepatitis C patient .</brief_summary>
	<brief_title>Comparison Efficacy Safety Between Interferon Alfacon-1 Alone Concomitant Dosing With Ribavirin Treatment Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon alfacon-1</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Hepatitis C patient ( high titer , genotype1 ) Patients autoimmune disorder Patients negative HBs antigen Patients hepatic cirrhosis , hepatic failure hepatic cancer Patients depression psychoneurotic disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Interferon alfacon-1</keyword>
	<keyword>Virus disease</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>